Boehringer Ingelheim registers Phase III trial of verducatib in COPD
The AIRWARD Study plans to enroll 1800 participants with COPD and plans to start on March 10, 2027. It evaluates whether verducatib reduces flare-ups and improves lung function compared with placebo over up to 1.5 years.
Primary source
ClinicalTrials.gov registry record, October 30, 2026
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Read the source: The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation